What changed for Endometriosis
A plain English summary of what recently moved in the public data Voxsanity tracks for Endometriosis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 151 to 152 (+1)
- Trials on record 827 to 832 (+5)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Endometriosis in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Endometriosis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04173169 · results posted 12 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04173169) enrolled 103 people in total — 53 in a group that took a 60-day course of an oral hormonal medication called a GnRH antagonist before starting IVF, and 50 in a comparison group that received either a placebo (a dummy pill) or standard IVF care. The trial's main goal was to measure how many people in each group went on to have a live birth (a baby born at 24 weeks of pregnancy or later). A number of secondary measurements were also recorded, including how many eggs were successfully fertilised, how many embryos we...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03216330 · results posted 8 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03216330) involved 56 participants in total — 37 in the "Case" group and 19 in the "Control" group. Of those, 36 Case participants and all 19 Control participants completed the study. The trial was measuring self-reported pain scores across three areas: pain felt deep during sexual intercourse, pain felt at the point of entry during sexual intercourse, and general pelvic pain experienced day-to-day. Participants rated their pain on a scale from 0 (no pain) to 10 (worst pain imaginable), and the scores were averaged over a...
-
NCT05622955 · results posted 6 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 35 participants, all of whom took part in something called "Endometriosis Group Care" — a group-based care programme for people with endometriosis. The trial ran over 8 weeks and was measuring changes in several areas including pain, physical function, sexual function, quality of life, anxiety, and depression. Of the 35 who started, 32 completed the programme and 3 did not finish. The reported data shows changes in scores from the start of the programme to its end at 8 weeks. For the main measure — how much pain inte...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06352840 · results posted 13 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 69 participants in total — 24 in a group called "Monitoring Progress Plus Usual Care" and 45 in a group called "My Pelvic Plan Plus Usual Care." The trial measured three things using standardised questionnaires: how much pain interfered with daily life, how intense the pain was, and how confident participants felt in managing their own symptoms. These were measured at two time points. It is worth noting that a significant number of participants did not complete the trial — 16 from the first group and 18 from the secon...
-
NCT05229653 · results posted 28 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05229653) was set up to compare a low-dose ketamine treatment group against a control group. The trial was measuring pelvic pain — using a standard 0-to-10 pain rating scale called a Visual Analogue Scale (VAS), where 0 means no pain and 10 means the worst pain imaginable — as well as anxiety levels, using a 7-question anxiety questionnaire called the GAD-7 (scored 0–21, where higher scores indicate more severe anxiety). In total, only 1 participant was recorded as having started the trial, in the low-dose ketamine group,...
-
NCT04039204 · results posted 26 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04039204) involved a total of 10 participants, split evenly into two groups of 5 — one group received a medication called Elagolix, and the other received an oral contraceptive pill called Ortho Cyclen. All 5 participants in the Elagolix group completed the study, while 3 out of 5 completed it in the oral contraceptive group (2 did not finish). The trial was measuring outcomes related to pregnancy, including live births, miscarriages, and viable pregnancies (pregnancies that continued and appeared to be progressing). The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03992846 · results posted 29 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03992846) enrolled 484 people across three groups to study treatments for endometriosis-associated pain. Participants were randomly assigned to receive either a lower dose of a medicine called LGX at 75 mg (160 people), a higher dose of LGX at 200 mg combined with another medicine called ABT (162 people), or a placebo — a dummy treatment with no active ingredient (162 people). The trial ran for six months and focused on two main types of pain linked to endometriosis: period pain (called dysmenorrhea) and pelvic pain that o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03654274 · results posted 20 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03654274) enrolled 802 participants across three groups: one group received relugolix combined with oestradiol and norethindrone acetate (E2/NETA) from the start (Group A, 278 people); a second group received relugolix with E2/NETA added in after a delay (Group B, 247 people); and a third group received a placebo, meaning a dummy pill with no active ingredient (Group C, 277 people). The trial measured two types of pelvic pain common in endometriosis — period pain (called dysmenorrhea) and non-menstrual pelvic pain (NMPP) —...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02214550 · results posted 18 June 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 353 participants across nine groups. Most participants were not given any treatment and served as comparison groups — including healthy volunteers, people with chronic pain, and people with painful bladder conditions. The groups who received an intervention were women with period pain and bladder sensitivity (a condition the trial called "dysmenorrhea with cross-organ sensitisation"), who were given either no oral contraceptive pill, a cyclic (on-and-off) version of a pill called Microgestin 1/20, or a cont...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03956082 · results posted 17 November 2022
According to the results reported on ClinicalTrials.gov, this was a small single-group study — meaning there was no comparison group — that enrolled 15 people. Nine participants completed the study, and six did not complete it. The trial was looking at a laparoscopic (keyhole) surgical procedure, specifically examining whether surgeons could maintain a consistent level of gas pressure inside the abdomen (called intra-abdominal pressure) throughout the operation without needing to increase it, and how clearly surgeons could see the operating area during the procedure. The reported data shows t...
-
NCT03970330 · results posted 3 November 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03970330) enrolled a total of 9 people — 5 in the low-dose naltrexone group and 4 in the placebo (dummy treatment) group. All 9 participants completed the trial. The study was looking at pain levels in people with endometriosis over 12 weeks, measuring daily pain on a 0–100 scale and combining those daily scores into a single total figure (called an "area under the curve," which is simply a way of adding up all the daily pain scores over the whole study period). The study also tracked quality of life, patients' own sense o...
-
NCT02921763 · results posted 13 June 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 women who were all given a medication called dydrogesterone. The trial was measuring changes in ovarian chocolate cysts (fluid-filled growths on the ovaries linked to endometriosis) as well as changes in period pain over time. Of the 60 women who started, 42 completed the trial and 18 did not finish. The reported data shows that when looking at cyst size after treatment, of the 26 participants with measurable cyst data at the end of the study, 13 were recorded as having a decreased cyst volume, 13 as unchanged, an...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03654326 · results posted 7 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03654326) enrolled 187 participants — 94 in the gefapixant group and 93 in the placebo group (a placebo is a dummy treatment with no active ingredient, used for comparison). The trial was measuring changes in daily pelvic pain scores in people with endometriosis-related pelvic pain, using a scale of 0 to 10 where 0 meant no pain and 10 meant extremely severe pain. It also tracked how many participants experienced an unwanted medical event (called an adverse event) during the study, and how many stopped taking the study dru...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00784693 · results posted 30 April 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called tanezumab compared to a placebo (a dummy treatment with no active ingredient) in people with endometriosis-related pain. A total of 23 people were assigned to tanezumab and 25 to placebo, with 22 and 25 respectively actually receiving treatment. By the end of the study, 20 people in the tanezumab group and 19 in the placebo group had completed it. The main thing being measured was the change in participants' self-rated daily endometriosis pain over eight weeks, using a scale from 0 (no pain) to 10 (...
-
NCT03573336 · results posted 22 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03573336) enrolled a very small number of participants — 2 people in the vilaprisan 2 mg group, 4 people in the vilaprisan 4 mg group, and 2 people in the placebo group (a dummy treatment with no active ingredient). Notably, none of the participants completed the study; all 8 withdrew before finishing. The trial was measuring pelvic pain related to endometriosis using an 11-point scale (where 0 means no pain and 10 means the worst imaginable pain), as well as how much pain relief medication participants used. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00621179 · results posted 5 October 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 37 people across four groups (12 in Group 1, 8 in Group 2, 7 in Group 3, and 10 in Group 4). The trial was looking at how people responded to a process called controlled ovarian hyperstimulation — a procedure used as part of fertility treatment where the ovaries are stimulated to produce eggs. The main thing being measured was whether an embryo successfully implanted in the womb, which was confirmed by an ultrasound at around six and a half weeks. Most participants completed the trial, with one person in Group 3 and o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01553201 · results posted 8 July 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01553201) involved 30 people in total, split into two equal groups of 15. One group received Botulinum Toxin (BoNT, commonly known as Botox), and the other received a placebo (an inactive substance). All 30 participants completed the trial with no drop-outs. The main thing the trial was measuring was whether participants reported an improvement in their pain symptoms — this was recorded simply as a yes or no answer for each person. The reported data shows that, out of the 15 people in the Botulinum Toxin group, 11 reporte...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01464775 · results posted 20 April 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01464775) looked at two different methods of viewing the inside of the body during surgery for suspected endometriosis — a technique called Narrow Band Imaging (NBI), which uses a special light to highlight tissue, and standard White Light imaging. A total of 167 people were enrolled across both groups: 123 in the NBI group and 44 in the White Light group. By the end of the study, 112 people in the NBI group and 38 in the White Light group had completed the trial. The reported data shows two main things were measured. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01728454 · results posted 23 July 2019
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called telapristone acetate in two doses (6 mg and 12 mg) compared to a placebo (a dummy pill with no active ingredient) in people with endometriosis-related pain. A total of 60 participants were enrolled across three groups — 17 in the placebo group, 20 in the 6 mg group, and 23 in the 12 mg group — across the first two stages of the trial. A smaller follow-on stage involved 22 of those participants. The trial measured changes in three types of pain — period pain (dysmenorrhea), pain during sex (dyspareunia),...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00958412 · results posted 12 February 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT00958412) enrolled 18 participants, all of whom received a treatment called Proellex (also written as Proellex®), taken once daily. The trial was set up to track any unwanted or unexpected health events (called adverse events) that participants experienced while taking the treatment, as a way of examining its safety profile. The reported data shows that none of the 18 participants completed the trial — all 18 did not finish. In terms of the main outcome being measured, the reported data shows that 16 out of the 18 partici...
-
NCT01620528 · results posted 18 September 2018
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called elagolix in women with endometriosis-associated pain. A total of 872 women took part — 374 received a dummy pill (placebo), 249 received a lower dose of elagolix (150 mg once a day), and 249 received a higher dose (200 mg twice a day). The trial measured two main types of pain: period pain (called dysmenorrhea) and pelvic pain between periods (called non-menstrual pelvic pain), as well as overall pain scores and painkiller use. The reported data shows that, for period pain at three months, 19.6% of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01931670 · results posted 7 September 2018
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called elagolix in women with endometriosis-related pain. A total of 815 women took part across three groups: 360 received a placebo (a dummy treatment with no active ingredient), 226 received a lower dose of elagolix (150 mg once a day), and 229 received a higher dose (200 mg twice a day). The trial mainly measured two types of pain over three months — period pain (called dysmenorrhea) and pelvic pain that occurs outside of periods (called non-menstrual pelvic pain) — using a diary scale of 0 (no pain) to...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00619866 · results posted 7 September 2018
According to the results reported on ClinicalTrials.gov, this trial involved women with endometriosis and tested two doses of a medicine called elagolix — 150 mg and 250 mg — against a placebo (a dummy treatment with no active ingredient). A total of 155 women started the first 12-week phase: 52 received placebo, 51 received elagolix 150 mg, and 52 received elagolix 250 mg. After week 12, women who had been on placebo were switched to one of the two elagolix doses for a further 12 weeks. The main thing being measured was how much participants' daily endometriosis pain scores changed over the f...
-
NCT02203331 · results posted 4 January 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02203331) enrolled 319 participants across six groups. Each group received a different combination of a vaginal ring (IVR) and an injection — some containing active ingredients at varying doses, and some containing placebos (inactive treatments used for comparison). The trial was measuring changes in period-related pelvic pain (endometriosis-associated pelvic pain, or EAPP) over roughly 84 days (three 28-day cycles). Pain was rated by participants daily on a scale of 0 to 10, where 0 meant no pain and 10 meant the worst im...
-
NCT01190475 · results posted 14 December 2017
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called BGS649 in a very small number of participants — just six people in total. Two people received a higher dose of BGS649, two received a lower dose, and two received a placebo (a dummy treatment with no active ingredient). Five of the six participants completed the study; one person in the placebo group did not finish. The trial was primarily measuring whether participants developed two or more egg follicles (small fluid-filled sacs in the ovaries where eggs develop) that reached a certain size — at least...
-
NCT01294371 · results posted 22 July 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 391 participants, all of whom received a hormone treatment called leuprorelin (390 were actually treated). The trial was looking at how often women taking leuprorelin for six months were also given "add-back therapy" — that is, additional hormones or other medicines sometimes used alongside leuprorelin to ease side effects related to lower oestrogen levels. By the end of the study, 357 participants had completed it, and 34 did not finish. The reported data shows that 46.5% of participants overall received some form o...
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding is currently being directed toward endometriosis in the United States. The direction of that funding has remained broadly steady over recent years, which suggests that scientific interest in the condition is consistent rather than declining. For patients, this signals that endometriosis continues to be taken seriously a...
See the full Endometriosis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.